Calamos Advisors LLC Makes New Investment in SiBone (NASDAQ:SIBN)

Calamos Advisors LLC acquired a new position in SiBone (NASDAQ:SIBN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 65,462 shares of the company's stock, valued at approximately $918,000. Calamos Advisors LLC owned about 0.15% of SiBone as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Johnson Investment Counsel Inc. purchased a new position in shares of SiBone in the first quarter worth $148,000. Rhumbline Advisers raised its position in SiBone by 3.6% in the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock worth $838,000 after buying an additional 2,100 shares during the last quarter. MetLife Investment Management LLC raised its position in SiBone by 17.6% in the 4th quarter. MetLife Investment Management LLC now owns 27,421 shares of the company's stock worth $384,000 after buying an additional 4,104 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in SiBone in the 4th quarter worth about $155,000. Finally, Deutsche Bank AG raised its holdings in shares of SiBone by 53.0% during the fourth quarter. Deutsche Bank AG now owns 36,268 shares of the company's stock valued at $508,000 after purchasing an additional 12,561 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SiBone Stock Performance

Shares of NASDAQ SIBN traded up $0.22 during midday trading on Tuesday, hitting $18.24. 20,709 shares of the company's stock traded hands, compared to its average volume of 393,700. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05. The stock has a market capitalization of $777.39 million, a price-to-earnings ratio of -28.43 and a beta of 0.93. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.53. The firm has a fifty day moving average of $17.89 and a 200 day moving average of $16.23.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The business had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. On average, analysts forecast that SiBone will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

SIBN has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of SiBone in a report on Tuesday, May 6th. Truist Financial boosted their target price on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th.

Insiders Place Their Bets

In other SiBone news, insider Anthony J. Recupero sold 3,310 shares of the company's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $18.27, for a total value of $60,473.70. Following the completion of the sale, the insider owned 279,121 shares in the company, valued at $5,099,540.67. This represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,127 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $18.29, for a total transaction of $57,192.83. Following the completion of the sale, the senior vice president directly owned 261,681 shares of the company's stock, valued at $4,786,145.49. This represents a 1.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 101,702 shares of company stock valued at $1,866,404. 3.90% of the stock is currently owned by corporate insiders.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.